Educational comparison — not medical advice. This page compares two compounds for informational purposes. Neither is recommended as treatment. Any protocol decision is a conversation with your licensed healthcare provider.
Ipamorelin is a GHRP (ghrelin receptor agonist) — binds the GH secretagogue receptor. CJC-1295 is a GHRH analog — binds the GHRH receptor. These are DIFFERENT receptors and mechanisms, which is why the two are commonly stacked together: synergistic GH release, not redundant. If choosing between them solo: CJC-1295 for smoother tonic elevation, ipamorelin for cleaner pulse-dependent profile.
FEATURE COMPARISON
Ipamorelin
CJC-1295
Full name
Ipamorelin
CJC-1295 (no DAC)
Category
Growth
Growth
FDA status
Not FDA-approved. Category 1 under the 2026 reclassification.
Not FDA-approved. Category 1 under the 2026 reclassification.
Half-life
~2 hours
~30 minutes (no DAC); several days (with DAC)
Typical dosing
200–300 mcg SC, 1–3× per day
100–200 mcg SC, 1–3× per day (typically no-DAC version)
Informational only — neither compound is presented as a treatment for any condition. These are contexts in which users research these compounds and discuss them with their licensed provider.
Informational comparison only — not medical advice. Research-stage compounds discussed are not FDA-approved unless specifically noted. Any protocol decision should be made with a licensed healthcare provider.